New hope for elderly myeloma patients: talquetamab trial opens
NCT ID NCT06827860
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called talquetamab in elderly patients whose multiple myeloma has come back after earlier treatments. The drug helps the body's immune cells attack the cancer. If the drug stops working, another drug called daratumumab may be added. The goal is to see if this approach can control the cancer with fewer side effects than more aggressive treatments like stem cell transplants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a single gene therapy turn the body into a Cancer-Fighting factory?
- Engineered immune cells take on incurable blood cancer
- New CAR T-Cell therapy targets Hard-to-Treat myeloma
- Could a simple shot replace hospital stays for myeloma patients?
- New hope for hard-to-treat myeloma: drug duo targets genetic weak spot